In the Drug and Chemical Toxicology Supplement entitled “Preclinical ADMET of Bilastine” (Drug Chem Toxicol 2012;35(S1):1-33) an error has been identified that we would like to make our readers aware of.
The ‘accepted dates’ for all articles within the supplement were listed as 31st March 2012, and the ‘received dates’ were listed as 28th March 2012, which is misleading. The articles were initially received by another Informa Healthcare publication (Xenobiotica) on 16th January 2012. The papers underwent full peer review, but the reviewers and editor felt the articles would be better suited to another journal. As a result the revised articles were submitted to Drug and Chemical Toxicology due to their better fit with the scope of this journal. The editor of Drug and Chemical Toxicology reviewed and accepted the articles in light of the initial peer review comments.
The articles concerned are listed below:
Whole-body tissue distribution of total radioactivity in rats after oral administration of [14C]-bilastine
María Luisa Lucero, and Andrew B. Patterson
Drug and Chemical Toxicology 2012;35(S1):1-7 DOI: 10.3109/01480545.2012.682650
Interactions of bilastine, a new oral H1 antihistamine, with human transporter systems
Maria Luisa Lucero, Ana Gonzalo, Alvaro Ganza, Nerea Leal, Itziar Soengas, Eniko Ioja, Szilvia Gedey, Mirza Jahic, and Dallas Bednarczyk
Drug and Chemical Toxicology 2012;35(S1): 8-17 DOI: 10.3109/01480545.2012.682653
An overview of bilastine metabolism during preclinical investigations
María Luisa Lucero, Ana Gonzalo, Rory Mumford, Mónica Betanzos, and Ana Alejandro
Drug and Chemical Toxicology 2012;35(S1):18–24 DOI: 10.3109/01480545.2012.682651
Preclinical toxicity profile of oral bilastine
María Luisa Lucero, Joseba K. Arteche, E. W. Sommer, and Agustín Casadesus
Drug and Chemical Toxicology 2012;35(S1):25–33 DOI: 10.3109/01480545.2012.682652
The Publisher apologise for this error and sincerely regret any inconvenience this may have caused our readers.